Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Disolf in STE-ACS Patients After Primary PCI
NCT02976701Phase 3Terminated
- Sponsor
- Dexa Medica
- Start
- Nov 2016
- Primary completion
- Jan 2023
- Modality
- Therapeutic Enzymes
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in ST elevation myocardial infarction (STEMI) comparing DLBS1033 with Placebo (2 arms). Primary endpoint: Index of microvascular resistance at 4 weeks. Started Nov 2016; status: terminated.
02
Drugs
DLBS1033
03
Conditions
ST elevation myocardial infarction (STEMI)
Beyond the preview
Go deeper on NCT02976701.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02976701.